<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
🌱 來自: [[5-Fluorouracil]]
 Capecitabine  &ldquo;Xeloda Tablet&rdquo; 500 mg/tab
  Dosing:  1,000-1,250 mg/m2 PO twice daily × 2 wks every 21 d."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-mlkgi530p-htlin222.vercel.app/api/blog?templateTitle=Capecitabine"><title>Capecitabine</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel=alternate type=application/rss+xml href=https://www.physician.tw//feed.xml title><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.720e2c4835986a3891d6eef3a55faa22.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.9422ebf6ba0889a950feb47330bafa38.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.8c890c0ab5916d5b1ce74859205052b4.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Capecitabine</h1><p class=meta>最後更新於
Sep 5, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Capecitabine.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags><li><a href=https://www.physician.tw/tags/building/>building</a></li></ul><blockquote class=info-callout><p></p><p>🌱 來自: <a href=/fluorouracil rel=noopener class=internal-link data-src=/fluorouracil>5-Fluorouracil</a></p></blockquote><a href=#capecitabine><h1 id=capecitabine><span class=hanchor arialabel=Anchor># </span>Capecitabine</h1></a><blockquote><p>&ldquo;Xeloda Tablet&rdquo; 500 mg/tab</p></blockquote><ul><li>Dosing:<ul><li>1,000-1,250 mg/m2 PO twice daily × 2 wks every 21 d.</li><li>Renal: CrCl 30-50 mL/min: 75% of dose; CrCl &lt;30 mL/min: use contraindicated</li></ul></li><li>PK/PD:<ul><li>Oral prodrug of 5-FU, converted via <a href=/step-activation-process-of-capecitabine rel=noopener class=internal-link data-src=/step-activation-process-of-capecitabine>3-step activation process</a> 󰒖.</li><li>Bioavailability ∼80%, protein binding &lt;60%, hepatic & tissue metabolism (active metabolite: 5-FU), renal excretion (96%), T1/2 0.5-1 h</li></ul></li><li>AEs:<ul><li>Diarrhea,</li><li><a href=/hand-foot-syndrome rel=noopener class=internal-link data-src=/hand-foot-syndrome>hand-foot syndrome</a>,</li><li>myelosuppression,</li><li>mucositis,</li><li>neurologic tox,</li><li>coronary vasospasm</li></ul></li><li>DDI: Inhibits CYP2C9 weakly, warfarin (BBW), oral anticoagulants (↑ levels of anticoagulants), phenytoin (↑ levels of phenytoin), leucovorin (↑ tox of capecitabine)</li><li>Clinical pearls: Increased risk of fatal/sev. AEs w/ DPD deficiency. Available as 150-mg & 500-mg tablets, take w/in 30 min after a meal, radiation sensitizer, uridine triacetate used as antidote in cases of overdose, accidental ingestion, & possible DPD deficiency</li></ul><p><a href=/three-step-metabolic-conversion-of-capecitabine-to-fluorouracil rel=noopener class=internal-link data-src=/three-step-metabolic-conversion-of-capecitabine-to-fluorouracil>Three-step metabolic conversion of capecitabine to fluorouracil</a></p><hr><ul><li>Used alone as adjuvant therapy following the complete resection of primary tumor in patients with stage III (Dukes’ C) colon cancer when treatment with fluoropyrimidine therapy alone is → preferred. [ref]</li><li>Combined therapy with IV oxaliplatin</li><li>is → a reasonable choice (accepted, treatment option) as adjuvant therapy following complete resection of primary tumor in patients with stage III colon cancer. [ref]</li><li>Initial (first-line) treatment of metastatic colorectal cancer when fluoropyrimidine therapy alone is → preferred.</li><li>Potential inhibition of CYP2C9.</li></ul><a href=#contraindications><h2 id=contraindications><span class=hanchor arialabel=Anchor># </span>Contraindications</h2></a><ul><li>Severe renal impairment (Clcr &lt;30 mL/minute). [ref]</li><li>Warnings/Precautions<ul><li>Coagulopathy</li><li>Generally occurs within several days to months following initiation of therapy; similar events reported in at ↣ least a few patients within 1 month following discontinuance of therapy.</li><li>Alterations in anticoagulant effect associated with capecitabine therapy reported in patients with or without liver metastases. [ref]</li><li>Age >60 years and diagnosis of cancer are independent variables predisposing patients to an increased risk of coagulopathy. [ref]</li><li>Monitor anticoagulant response (PT or INR) frequently, and adjust the anticoagulant dose accordingly in patients receiving concomitant therapy. [ref](See Specific Drugs under Interactions.)
<a href=/fluoropyrimidines rel=noopener class=internal-link data-src=/fluoropyrimidines>fluoropyrimidine</a></li></ul></li></ul><a href=#第三代-fluoropyrimidine-藥物-capecitabine-在結腸直腸癌治療中的--應用-><h2 id=第三代-fluoropyrimidine-藥物-capecitabine-在結腸直腸癌治療中的--應用-><span class=hanchor arialabel=Anchor># </span>第三代 fluoropyrimidine 藥物 Capecitabine 在結腸直腸癌治療中的 → 應用 🩺</h2></a><ul><li>Capecitabine 是屬於第三代的 fluoropyrimidine 藥物，在2001年被美國 FDA 核准用於結腸直腸癌的 → 治療。</li><li>Capecitabine 會在肝臟中經由 carboxylesterase 水解，再經由 cytidine deaminase 轉換成 5&rsquo;-deoxy-5-fluorouridine，最後在腫瘤細胞內由 thymidine phosphorylase 形成5-FU。</li><li>這種選擇性的 → 代謝過程能讓腫瘤細胞內聚集高濃度的 → 5-FU，提高抗癌效果，同時減少 ↓ 其他正常細胞的 → 危險暴露， ∴ 因此副作用相對較小。</li><li>Capecitabine 的 → 反應率約為24-35%，整體存活時間約為11-20個月<ul><li>併用 LV 效果並 ✖ 不會更好， ∴ 因此標準療程中 ✖ 不建議加入 LV。 🩺</li></ul></li></ul><a href=#capecitabine-的--作用機制-><h2 id=capecitabine-的--作用機制-><span class=hanchor arialabel=Anchor># </span>Capecitabine 的 → 作用機制 🧬</h2></a><ul><li>Capecitabine 是一種 5-FU 前藥，能夠迅速地被完整地吸收，並經過三步代謝作用變成 5-FU。<ul><li>它在肝臟中被酯水解酶轉換為 5&rsquo;-deoxy-5-fluorocytidine，</li><li>然後在腫瘤和肝細胞中被胞嘧啶脫氨酶轉換為 5&rsquo;-deoxy-5-fluorouridine，</li><li>最後由胸腺嘧啶磷酸化酶轉換為 5-FU。</li></ul></li><li>相比正常組織，腫瘤細胞中的 → <a href=/thymidine-phosphorylase rel=noopener class=internal-link data-src=/thymidine-phosphorylase>Thymidine phosphorylase</a> 胸腺嘧啶磷酸化酶含量更高，<ul><li>∴ 因此 Capecitabine 能夠在腫瘤細胞中產生 ↪ 更高的 5-FU 濃度，提高治療效果，同時降低 ↓ 對正常組織的 → 毒副作用。</li></ul></li></ul><a href=#capecitabine-在轉移性結直腸癌治療中的--療效評估-><h2 id=capecitabine-在轉移性結直腸癌治療中的--療效評估-><span class=hanchor arialabel=Anchor># </span>Capecitabine 在轉移性結直腸癌治療中的 → 療效評估 🩺</h2></a><ul><li><a href=https://www.nature.com/articles/6601676 rel=noopener>Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials | British Journal of Cancer</a></li><li>本研究利用來自兩個相同設計的 III 期研究中大量、具有良好特徵的 → 轉移性結直腸癌 (mCRC) 患者數據，評估了口服 Capecitabine 的 → 療效。</li><li>總計有1207名未接受過治療的 mCRC 患者被隨機分配到口服 Capecitabine (每21天兩次1250 mg m-2，第1-14天；n=603) 或靜脈 bolus 5-氟尿嘧啶/葉酸鈉 (5-FU/LV；Mayo Clinic 方案；n=604) 治療。</li><li>結果顯示，Capecitabine 的 → 反應率優於 5-FU/LV (26% vs. 17%；P&lt;0.0002)</li><li>亞組分析表明，即使在具有 ✖ 不良預後指標的 → 患者亞組中，Capecitabine 也能夠一致地產生 ↪ 更優異的 → 反應率 (P&lt;0.05) 。</li><li>儘管兩組的 → 中位反應時間和持續時間相似，但疾病進展時間 (TTP) 在兩組中相當 (風險比 (HR) 0.997，95%信心區間 (CI) 0.885-1.123，P=0.95；Capecitabine 和 5-FU/LV 的 → 中位 TTP 分別為 4.6 和 4.7 個月) 。</li><li>多變量 Cox 回歸分析確定年齡較小、肝轉移、多處轉移和較差的 Karnofsky 表現狀態是 TTP 不良預後指標的 → 獨立因素。</li><li>兩組的 → 整體生存率相同 (HR 0.95，95% CI 0.84-1.06，P=0.48；Capecitabine 和 5-FU/LV 的 → 中位生存期分別為 12.9 和 12.8 個月) 。</li><li>Capecitabine 與 i.v. 5-FU/LV 相比，在作為 mCRC 的 → 一線治療時，產生 ↪ 了更優異的 → 反應率、相當的 TTP 和整體生存率，並具有更好的 → 安全性和便利性</li><li>對於需要氟嘧啶單獨治療的 → 患者，應強烈考慮使用 Capecitabine</li><li>在 I 期和 II 期試驗取得鼓舞人心的 → 結果後，正在進行 Capecitabine 聯合伊立替康、奧沙利銨和放療的 → 隨機試驗</li><li>Capecitabine 是取代 i.v. 5-FU 作為結直腸癌治療基礎的 → 合適藥物。</li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li>🤭沒有找到反向連結</li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><p><a href=https://www.buymeacoffee.com/htl.lizard><img src=https://cdn.buymeacoffee.com/buttons/v2/default-yellow.png width=200></a></p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/htlin.lizard>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://htlin222.medium.com>Medium</a></li></ul></footer></div></div></body></html>